In December 2019,a new type of pneumonia caused by the coronavirus (COVID-2019) broke out in
Wuhan ,China, and spreads quickly to other Chinese cities and 28 countries. More than 70000
people were infected and over 2000 people died all over the world. There is no specific drug
treatment for this disease. Considering that lung damage is related to both viral infection
and burst of cytokines, our idea is to evaluate the efficacy and safety of escin as add-on
treatment to conventional antiviral drugs in COVID-19 infected patients.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
University of Catanzaro
Collaborators:
Azienda Ospedaliera Pugliese Ciaccio Azienda Ospedaliera Universitaria Mater Domini, Catanzaro